Cetus May Have A Surprise In Store

Biotech stocks have been hit by profit-taking of late as investors worry that the high-flying group may be vulnerable in a market downturn. Even so, Cetus, a major developer of recombinant-DNA drugs to fight cancers and other diseases, has resumed its upswing.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.